Perspective

You have full text access to this OnlineOpen article

Perspective: Assessing the Clinical Utility of Serum CTX in Postmenopausal Osteoporosis and Its Use in Predicting Risk of Osteonecrosis of the Jaw†

  1. Sanford Baim*,
  2. Paul D Miller

Article first published online: 16 FEB 2009

DOI: 10.1359/jbmr.090203

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 24, Issue 4, pages 561–574, April 2009

Additional Information

How to Cite

Baim, S. and Miller, P. D. (2009), Perspective: Assessing the Clinical Utility of Serum CTX in Postmenopausal Osteoporosis and Its Use in Predicting Risk of Osteonecrosis of the Jaw. J Bone Miner Res, 24: 561–574. doi: 10.1359/jbmr.090203

Author Information

  1. Colorado Center for Bone Research, Lakewood, Colorado, USA

*Address reprint requests to: Sanford Baim, MD, FACR, CCD, Colorado Center for Bone Research, Suite 250, 3190 S. Wadsworth Boulevard, Lakewood, CO 80227, USA

  1. †

    Dr Baim has received scientific grants from Procter & Gamble, Sanofi-Aventis, Roche, Eli Lilly and Co., Merck, Novartis, and Amgen. Dr Miller has received scientific grants from Procter & Gamble, Sanofi-Aventis, Roche, Eli Lilly and Co., Merck, Novartis, and Amgen and is a consultant/speaker's board member for Procter & Gamble, Sanofi-Aventis, Merck, Eli Lilly and Co., Amgen, NPS, Novartis, Roche, and GlaxoSmithKline. Neither Dr Baim nor Dr Miller has an equity position in any pharmaceutical company.

Publication History

  1. Issue published online: 4 DEC 2009
  2. Article first published online: 16 FEB 2009
  3. Manuscript Accepted: 9 FEB 2009
  4. Manuscript Revised: 16 JAN 2009
  5. Manuscript Received: 10 DEC 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (542K)

REFERENCES

  • 1
    Vaananen HK, Zhao H, Mulari M, Halleen JM 2000 The cell biology of osteoclast function. J Cell Sci 113: 377–381.
  • 2
    Manolagas SC 2000 Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21: 115–137.
  • 3
    Watts NB 1999 Clinical utility of biochemical markers of bone remodeling. Clin Chem 45: 1359–1368.
  • 4
    Garnero P, Borel O, Delmas PD 2001 Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 47: 694–702.
  • 5
    Christgau S, Cloos PA 2003 Current and future applications of bone turnover markers. Clin Lab (Zaragoza) 49: 439–446.
  • 6
    Akesson K 1995 Biochemical markers of bone turnover. A review. Acta Orthop Scand 66: 376–386.
  • 7
    Seibel MJ 2005 Biochemical markers of bone turnover: Part I: Biochemistry and variability. Clin Biochem Rev 26: 97–122.
  • 8
    Eastell R, Robins SP, Colwell T, Assiri AM, Riggs BL, Russell RG 1993 Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption. Osteoporos Int 3: 255–260.
  • 9
    Calvo MS, Eyre DR, Gundberg CM 1996 Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev 17: 333–368.
  • 10
    Caulfield MP, Reitz RE 2004 Biochemical markers of bone turnover and their utility in osteoporosis. MLO Med Lab Obs 36: 34–37.
  • 11
    Gomez B Jr , Ardakani S, Ju J, Jenkins D, Cerelli MJ, Daniloff GY, Kung VT 1995 Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 41: 1560–1566.
  • 12
    Melkko J, Niemi S, Risteli L, Risteli J 1990 Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 36: 1328–1332.
  • 13
    Garnero P, Vergnaud P, Hoyle N 2008 Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem 54: 188–196.
  • 14
    Miller PD, Baran DT, Bilezikian JP, Greenspan SL, Lindsay R, Riggs BL, Watts NB 1999 Practical clinical application of biochemical markers of bone turnover: Consensus of an expert panel. J Clin Densitom 2: 323–342.
  • 15
    Withold W 1996 Monitoring of bone turnover biological, preanalytical and technical criteria in the assessment of biochemical markers. Eur J Clin Chem Clin Biochem 34: 785–799.
  • 16
    North American Menopause Society 2002 Management of postmenopausal osteoporosis: Position statement of the North American Menopause Society. Menopause 9: 84–101.
  • 17
    Recker R, Lappe J, Davies K, Heaney R 2000 Characterization of perimenopausal bone loss: A prospective study. J Bone Miner Res 15: 1965–1973.
    Direct Link:
  • 18
    Christgau S, Rosenquist C, Alexandersen P, Bjarnason NH, Ravn P, Fledelius C, Herling C, Qvist P, Christiansen C 1998 Clinical evaluation of the serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem 44: 2290–2300.
  • 19
    Christgau S, Bitsch-Jensen O, Hanover Bjarnason N, Gamwell Henriksen E, Qvist P, Alexandersen P, Bang Henriksen D 2000 Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 26: 505–511.
  • 20
    Kraenzlin ME 2006 Practical use of biochemical markers of bone turnover. Ann Endocrinol (Paris) 67: 155–156.
  • 21
    Garnero P, Gineyts E, Riou JP, Delmas PD 1994 Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 79: 780–785.
  • 22
    Sebba AI, Broy S, Kohles JD, Weissman P 2008 Rapid suppression of bone resorption marker levels with ibandronate therapy in a bisphosphonate-naive population. J Clin Densitom 11: 417–423.
  • 23
    Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE 2005 Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized double-blind study. J Bone Miner Res 20: 141–151.
    Direct Link:
  • 24
    Marx RE, Cillo JE Jr , Ulloa JJ 2007 Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65: 2397–2410.
  • 25
    Marx RE 2008 Bisphosphonate-induced osteonecrosis of the jaws: A challenge, a responsibility, and an opportunity. Int J Periodontics Restorative Dent 28: 5–6.
  • 26
    Sawatari Y, Marx RE 2007 Bisphosphonates and bisphosphonate induced osteonecrosis. Oral Maxillofac Surg Clin North Am 19: 487–498.
  • 27
    Zak M, Spina AM, Spinazze RP, Perkinson WL, Spinazze DJ 2007 Bisphosphonates and the dental patient: Part 2. Compend Contin Educ Dent 28: 510–515.
  • 28
    Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E 2008 Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 66: 1320–1321.
  • 29
    Delmas PD 1993 Biochemical markers of bone turnover for the clinical investigation of osteoporosis. Osteoporos Int 3 (Suppl 1): 81–86.
  • 30
    Seibel MJ, Lang M, Geilenkeuser WJ 2001 Interlaboratory variation of biochemical markers of bone turnover. Clin Chem 47: 1443–1450.
  • 31
    Leeming DJ, Alexandersen P, Karsdal MA, Qvist P, Schaller S, Tanko LB 2006 An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice. Eur J Clin Pharmacol 62: 781–792.
  • 32
    Garnero P, Delmas PD 1998 Biochemical markers of bone turnover. Applications for osteoporosis. Endocrinol Metab Clin North Am 27: 303–323.
  • 33
    Pedersen BJ, Ravn P, Bonde M 1998 Type I collagen C-telopeptide degradation products as bone resorption markers. Clin Ligand Assay 21: 118–127.
  • 34
    Rosen HN, Moses AC, Garber J, Iloputaife ID, Ross DS, Lee SL, Greenspan SL 2000 Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 66: 100–103.
  • 35
    Fledelius C, Johnsen AH, Cloos PA, Bonde M, Qvist P 1997 Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha1) region. J Biol Chem 272: 9755–9763.
  • 36
    Nordic Bioscience Diagnostics 2002 Serum CrossLaps ELISA [package insert]. Nordic Bioscience Diagnostics, Herlev, Denmark.
  • 37
    Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C 1994 Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 40: 2022–2025.
  • 38
    Ju HS, Leung S, Brown B, Stringer MA, Leigh S, Scherrer C, Shepard K, Jenkins D, Knudsen J, Cannon R 1997 Comparison of analytical performance and biological variability of three bone resorption assays. Clin Chem 43: 1570–1576.
  • 39
    Plebani M, Bernardi D, Meneghetti MF, Ujka F, Zaninotto M 2000 Biological variability in assessing the clinical value of biochemical markers of bone turnover. Clin Chim Acta 299: 77–86.
  • 40
    Seibel MJ, Koeller M, Van der Velden B, Diel I 2002 Long-term variability of bone turnover markers in patients with non-metastatic breast cancer. Clin Lab (Zaragoza) 48: 579–582.
  • 41
    Takahashi M, Kawana K, Nagano A 2002 Biological variability of biochemical markers of bone turnover in healthy women. Endocr Res 28: 257–264.
  • 42
    Allende-Vigo MZ 2007 The use of biochemical markers of bone turnover in osteoporosis. P R Health Sci J 26: 91–95.
  • 43
    Blumsohn A, Eastell R 1997 The performance and utility of biochemical markers of bone turnover: Do we know enough to use them in clinical practice ? Ann Clin Biochem 34: 449–459.
  • 44
    Blumsohn A, Colwell A, Naylor K, Eastell R 1995 Effect of light and gamma-irradiation on pyridinolines and telopeptides of type I collagen in urine. Clin Chem 41: 1195–1197.
  • 45
    Colwell A, Hamer A, Blumsohn A, Eastell R 1996 To determine the effects of ultraviolet light, natural light and ionizing radiation on pyridinium cross-links in bone and urine using high-performance liquid chromatography. Eur J Clin Invest 26: 1107–1114.
    Direct Link:
  • 46
    Qvist P, Munk M, Hoyle N, Christiansen C 2004 Serum and plasma fragments of C-telopeptides of type I collagen (CTX) are stable during storage at low temperatures for 3 years. Clin Chim Acta 350: 167–173.
  • 47
    Quidel 2002 Quidel Metra BAP EIA Kit [package insert]. Quidel, San Diego, CA.
  • 48
    Roche Diagnostics. Analytical data for serum bone markers, Available online at http://www.roche.com/prod_diag_bone-m-1.pdf . Accessed on Sept 12, 2008.
  • 49
    Seibel MJ, Woitge HW, Farahmand I, Oberwittler H, Ziegler R 1998 Automated and manual assays for urinary crosslinks of collagen: Which assay to use ? Exp Clin Endocrinol Diabetes 106: 143–148.
  • 50
    Hannon R, Eastell R 2000 Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 11 (Suppl 6): S30–S44.
  • 51
    Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C 2002 Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): Effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 31: 57–61.
  • 52
    Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R 2002 Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 30: 886–890.
  • 53
    Hla MM, Davis JW, Ross PD, Yates AJ, Wasnich RD 2001 The relation between lifestyle factors and biochemical markers of bone turnover among early postmenopausal women. Calcif Tissue Int 68: 291–296.
  • 54
    Chiu KM, Ju J, Mayes D, Bacchetti P, Weitz S, Arnaud CD 1999 Changes in bone resorption during the menstrual cycle. J Bone Miner Res 14: 609–615.
    Direct Link:
  • 55
    Schlemmer A, Hassager C 1999 Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption. Eur J Endocrinol 140: 332–337.
  • 56
    Glover SJ, Garnero P, Naylor K, Rogers A, Eastell R 2008 Establishing a reference range for bone turnover markers in young, healthy women. Bone 42: 623–630.
  • 57
    Christgau S 2000 Circadian variation in serum CrossLaps concentration is reduced in fasting individuals. Clin Chem 46: 431.
  • 58
    Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J 2000 The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 11 (Suppl 6): S2–S17.
  • 59
    Glover S, Gall M, Schoenborn-Kellenberger O, Wagener M, Garnero P, Boonen S, Cauley J, Black D, Delmas P, Eastell R 2009 Establishing a reference interval for bone turnover markers in 637 healthy, young, pre-menopausal women from UK, France, Belgium and the USA. J Bone Miner Res 24: 389–397.
    Direct Link:
  • 60
    de Papp AE, Bone HG, Caulfield MP, Kagan R, Buinewicz A, Chen E, Rosenberg E, Reitz RE 2007 A cross-sectional study of bone turnover markers in healthy premenopausal women. Bone 40: 1222–1230.
  • 61
    Adami S, Bianchi G, Brandi ML, Giannini S, Ortolani S, Dimunno O, Frediani B, Rossini M 2008 Determinants of bone turnover markers in healthy premenopausal women. Calcif Tissue Int 82: 341–347.
  • 62
    Srivastava AK, Vliet EL, Lewiecki EM, Maricic M, Abdelmalek A, Gluck O, Baylink DJ 2005 Clinical use of serum and urine bone markers in the management of osteoporosis. Curr Med Res Opin 21: 1015–1026.
  • 63
    National Osteoporosis Foundation 2008 Clinician's guide to prevention and treatment of osteoporosis. Available online at http://www.nof.org/professionals/NOF_Clinicians_Guide.pdf Accessed October 30, 2008.
  • 64
    Fink E, Cormier C, Steinmetz P, Kindermans C, Le Bouc Y, Souberbielle JC 2000 Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporos Int 11: 295–303.
  • 65
    Garnero P, Mulleman D, Munoz F, Sornay-Rendu E, Delmas PD 2003 Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: The OFELY study. J Bone Miner Res 18: 1789–1794.
    Direct Link:
  • 66
    Scariano JK, Garry PJ, Montoya GD, Wilson JM, Baumgartner RN 2001 Critical differences in the serial measurement of three biochemical markers of bone turnover in the sera of pre- and postmenopausal women. Clin Biochem 34: 639–644.
  • 67
    Looker AC, Bauer DC, Chesnut CH III , Gundberg CM, Hochberg MC, Klee G, Kleerekoper M, Watts NB, Bell NH 2000 Clinical use of biochemical markers of bone remodeling: Current status and future directions. Osteoporos Int 11: 467–480.
  • 68
    Gluer CC, Blake G, Lu Y, Blunt BA, Jergas M, Genant HK 1995 Accurate assessment of precision errors: How to measure the reproducibility of bone densitometry techniques. Osteoporos Int 5: 262–270.
  • 69
    Bonnick SL 2004 Monitoring changes in bone density. In: BonnickSL (ed.) Bone Densitometry in Clinical Practice: Application and Interpretation, 2nd ed. Humana Press, Totowa, NJ, USA 267–285.
  • 70
    Baim S, Wilson CR, Lewiecki EM, Luckey MM, Downs RW Jr , Lentle BC 2005 Precision assessment and radiation safety for dual-energy X-ray absorptiometry: Position paper of the International Society for Clinical Densitometry. J Clin Densitom 8: 371–378.
  • 71
    Schafer AL, Vittinghoff E, Ramachandran R, Mahmoudi N, Bauer DC 2007 Reproducibility of biochemical markers of bone turnover in clinical practice. J Bone Miner Res 22: S416.
  • 72
    Garnero P 2000 Markers of bone turnover for the prediction of fracture risk. Osteoporos Int 11 (Suppl 6): S55–S65.
  • 73
    Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD 1996 Markers of bone resorption predict hip fracture in elderly women: The EPIDOS Prospective Study. J Bone Miner Res 11: 1531–1538.
    Direct Link:
  • 74
    Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD 1999 Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: The OFELY study. J Bone Miner Res 14: 1614–1621.
    Direct Link:
  • 75
    Greenspan SL, Resnick NM, Parker RA 2005 Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: A three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 90: 2762–2767.
  • 76
    Kim SW, Park DJ, Park KS, Kim SY, Cho BY, Lee HK, Shin CS 2005 Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis. Endocr J 52: 667–674.
  • 77
    Ravn P, Clemmesen B, Christiansen C 1999 Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 24: 237–244.
  • 78
    Ravn P, Hosking D, Thompson D, Cizza G, Wasnich RD, McClung M, Yates AJ, Bjarnason NH, Christiansen C 1999 Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 84: 2363–2368.
  • 79
    Ravn P, Thompson DE, Ross PD, Christiansen C 2003 Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone 33: 150–158.
  • 80
    Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD 2004 Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The fracture intervention trial. J Bone Miner Res 19: 1250–1258.
    Direct Link:
  • 81
    Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18: 1051–1056.
    Direct Link:
  • 82
    Delmas PD, Vrijens B, Roux C, Le-Moigne-Amrani A, Eastell R, Grauer A, Watts NB, Pols HAP, Ringe JD, Cahall D 2003 A reinforcement message based on bone turnover marker response influences long-term persistence with risedronate in osteoporosis: The IMPACT study. J Bone Miner Res 18: S374.
  • 83
    Christiansen C, Riis BJ, Rodbro P 1990 Screening procedure for women at risk of developing postmenopausal osteoporosis. Osteoporos Int 1: 35–40.
  • 84
    Dresner-Pollak R, Parker RA, Poku M, Thompson J, Seibel MJ, Greenspan SL 1996 Biochemical markers of bone turnover reflect femoral bone loss in elderly women. Calcif Tissue Int 59: 328–333.
  • 85
    Christiansen C, Riis BJ, Rodbro P 1987 Prediction of rapid bone loss in postmenopausal women. Lancet 1: 1105–1108.
  • 86
    Lenora J, Ivaska KK, Obrant KJ, Gerdhem P 2007 Prediction of bone loss using biochemical markers of bone turnover. Osteoporos Int 18: 1297–1305.
  • 87
    Rogers A, Hannon RA, Eastell R 2000 Biochemical markers as predictors of rates of bone loss after menopause. J Bone Miner Res 15: 1398–1404.
    Direct Link:
  • 88
    Melton LJ, III , Khosla S, Atkinson EJ, O'Fallon WM, Riggs BL 1997 Relationship of bone turnover to bone density and fractures. J Bone Miner Res 12: 1083–1091.
    Direct Link:
  • 89
    Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD 2000 Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study. J Bone Miner Res 15: 1526–1536.
    Direct Link:
  • 90
    Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD 2005 Identification of osteopenic women at high risk of fracture: The OFELY study. J Bone Miner Res 20: 1813–1819.
    Direct Link:
  • 91
    Chesnut CH, Ettinger MP, Miller PD, Baylink DJ, Emkey R, Harris ST, Wasnich RD, Watts NB, Schimmer RC, Recker RR 2005 Ibandronate produces significant, similar antifracture efficacy in North American and European women: New clinical findings from BONE. Curr Med Res Opin 21: 391–401.
  • 92
    Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11: 83–91.
  • 93
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280: 2077–2082.
  • 94
    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356: 1809–1822.
  • 95
    Delmas PD, McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S 2008 Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 42: 36–42.
  • 96
    Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM 2006 Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study. Arthritis Rheum 54: 1838–1846.
    Direct Link:
  • 97
    Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C 2005 Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20: 1315–1322.
    Direct Link:
  • 98
    Division of Metabolic and Endocrine Drug Products-U.S. Food and Drug Administration 1994 Guidelines for preclinical and clinical evaluation of agents used in the prevention of treatment of postmenopausal osteoporosis. Available online at http://www.fda.gov/cder/guidance/osteo.pdf . Accessed November 12, 2008.
  • 99
    Silverman SL, Cummings SR, Watts NB 2008 Recommendations for the clinical evaluation of agents for treatment of osteoporosis: Consensus of an expert panel representing the American Society for Bone and Mineral Research (ASBMR), the International Society for Clinical Densitometry (ISCD), and the National Osteoporosis Foundation (NOF). J Bone Miner Res 23: 159–165.
    Direct Link:
  • 100
    Bonnick SL, Johnston CC Jr , Kleerekoper M, Lindsay R, Miller P, Sherwood L, Siris E 2001 Importance of precision in bone density measurements. J Clin Densitom 4: 105–110.
  • 101
    Binkley N, Bilezikian JP, Kendler DL, Leib ES, Lewiecki EM, Petak SM 2006 Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference. J Clin Densitom 9: 4–14.
  • 102
    Raisz L, Smith JA, Trahiotis M, Fall P, Shoukri K, Digennaro J, Sacco-Gibson N 2000 Short-term risedronate treatment in postmenopausal women: Effects on biochemical markers of bone turnover. Osteoporos Int 11: 615–620.
  • 103
    Miller PD 2007 Monitoring osteoporosis therapies. Curr Osteoporos Rep 5: 38–43.
  • 104
    Reginster JY, Collette J, Neuprez A, Zegels B, Deroisy R, Bruyere O 2008 Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone 42: 832–836.
  • 105
    Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB 1998 Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: A randomized clinical trial. J Bone Miner Res 13: 1431–1438.
    Direct Link:
  • 106
    Greenspan SL, Rosen HN, Parker RA 2000 Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab 85: 3537–3540.
  • 107
    Bauer DC, Vittinghof E 2008 Optimal thresholds, linear or nonlinear relationships of fracture risk reduction with therapy. J Bone Miner Res 23: 1349.
    Direct Link:
  • 108
    Eastell R, Hannon R, Garnero P, Campbell M, Delmas P 2008 Optimal thresholds, linear or nonlinear relationships of fracture risk reduction with therapy. J Bone Miner Res 23: 1350.
    Direct Link:
  • 109
    Reginster JY, Rabenda V, Neuprez A 2006 Adherence, patient preference and dosing frequency: Understanding the relationship. Bone 38: S2–S6.
  • 110
    Weycker D, Macarios D, Edelsberg J, Oster G 2006 Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17: 1645–1652.
  • 111
    Gold DT, McClung B 2006 Approaches to patient education: Emphasizing the long-term value of compliance and persistence. Am J Med 119: S32–S37.
  • 112
    Clowes JA, Peel NF, Eastell R 2004 The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: A randomized controlled trial. J Clin Endocrinol Metab 89: 1117–1123.
  • 113
    Delmas PD 2000 Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int 11 (Suppl 6): S66–S76.
  • 114
    Delmas PD, Vrijens B, Eastell R, Roux C, Pols HA, Ringe JD, Grauer A, Cahall D, Watts NB 2007 Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92: 1296–1304.
  • 115
    Chaiamnuay S, Saag KG 2006 Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates ? Rev Endocr Metab Disord 7: 101–112.
  • 116
    Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws-American Association of Oral and Maxillofacial Surgeons 2007 American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65: 369–376.
  • 117
    Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E 2007 Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22: 1479–1491.
    Direct Link:
  • 118
    Khan AA, Sandor GK, Dore E, Morrison AD, Alsahli M, Amin F, Peters E, Hanley DA, Chaudry SR, Dempster DW, Glorieux FH, Neville AJ, Talwar RM, Clokie CM, Al Mardini M, Paul T, Khosla S, Josse RG, Sutherland S, Lam DK, Carmichael RP, Blanas N, Kendler D, Petak S, St-Marie LG, Brown J, Evans AW, Rios L, Compston JE 2008 Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 35: 1391–1397.
  • 119
    American Dental Association Council on Scientific Affairs 2006 Dental management of patients receiving oral bisphosphonate therapy: Expert panel recommendations. J Am Dent Assoc 137: 1144–1150.
  • 120
    Peters E, Daley T 2003 Persistent painful ulcer of the posterior lingual mandibular mucosa. J Contemp Dent Pract 4: 71–75.
  • 121
    Farah CS, Savage NW 2003 Oral ulceration with bone sequestration. Aust Dent J 48: 61–64.
    Direct Link:
  • 122
    Kessler HP 2005 Oral and maxillofacial pathology case of the month. Lingual mandibular sequestration with ulceration. Tex Dent J 122: 198–199.
  • 123
    Neville B, Damm DD, Allen CM, Bouquot J Oral ulceration with bone sequestration (spontaneous sequestration and traumatic sequestration). In: Oral and Maxillofacial Pathology, 3rd ed. Elsevier Health Sciences, Pliladelphia, PA, USA, pp. 276–277.
  • 124
    Scully C 2002 Oral ulceration: A new and unusual complication. Br Dent J 192: 139–140.
  • 125
    Sonnier KE, Horning GM 1997 Spontaneous bony exposure: A report of 4 cases of idiopathic exposure and sequestration of alveolar bone. J Periodontol 68: 758–762.
  • 126
    Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P 2007 A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: Prevalence, risk factors, and clinical characteristics. Clin Ther 29: 1548–1558.
  • 127
    Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN 2008 Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23: 826–836.
    Direct Link:
  • 128
    Goldman ML, Denduluri N, Berman AW, Sausville R, Guadagnini JP, Kleiner DE, Brahim JS, Swain SM 2006 A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patient with metastatic breast cancer. Oncology 71: 306–308.
  • 129
    Walter C, Grotz KA, Kunkel M, Al-Nawas B 2007 Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 15: 197–202.
  • 130
    Nase JB, Suzuki JB 2006 Osteonecrosis of the jaw and oral bisphosphonate treatment. J Am Dent Assoc 137: 1115–1119.
  • 131
    Dannemann C, Gratz KW, Riener MO, Zwahlen RA 2007 Jaw osteonecrosis related to bisphosphonate therapy: A severe secondary disorder. Bone 40: 828–834.
  • 132
    Novartis Pharmaceuticals 2008 Zometa (zoledronic acid) [US prescribing information]. Novartis Pharmaceuticals, East Hanover, NJ, USA.
  • 133
    Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL 2004 Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62: 527–534.
  • 134
    Marx RE 2003 Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 61: 1115–1117.
  • 135
    Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA 2005 Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 23: 8580–8587.
  • 136
    Carter G, Goss AN, Doecke C 2005 Bisphosphonates and avascular necrosis of the jaw: A possible association. Med J Aust 182: 413–415.
  • 137
    Woo SB, Hellstein JW, Kalmar JR 2006 Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144: 753–761.
  • 138
    ICD-9-CM Index to Diseases Addenda (FY08) Centers of Disease Control and Prevention website. Available online at http://www.cdc.gov/nchs/datawh/ftpserv/ftpicd9/icdidx_addenda08.pdf. Accessed June 24, 2008.
  • 139
    Eisman JA, Garcia-Hernandez PA, Ortiz-Luna G, Ste-Marie LG, Hughes C, Mairon N, Masanauskaite D, Delmas PD 2006 Intermittent intravenous ibandronate injections are an effective treatment option in postmenopausal osteoporosis: 2-year results from Diva. Osteoporos Int 17: S212.
  • 140
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348: 1535–1541.
  • 141
    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III , Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282: 1344–1352.
  • 142
    Shane E, Goldring S, Christakos S, Drezner M, Eisman J, Silverman S, Pendrys D 2006 Osteonecrosis of the jaw: More research needed. J Bone Miner Res 21: 1503–1505.
    Direct Link:
  • 143
    Cartsos VM, Zhu S, Zavras AI 2008 Bisphosphonate use and the risk of adverse jaw outcomes: A medical claims study of 714,217 people. J Am Dent Assoc 139: 23–30.
  • 144
    Zavras AI, Zhu S 2006 Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: Is it osteonecrosis ? J Oral Maxillofac Surg 64: 917–923.
  • 145
    Pazianas M, Blumentals WA, Miller PD 2008 Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporos Int 19: 773–779.
  • 146
    Schwartz HC 2008 Serum CTX testing. J Oral Maxillofac Surg 66: 1319–1320.
  • 147
    Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR 2006 Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial. JAMA 296: 2927–2938.
  • 148
    Stakkestad JA, Lakatos P, Lorenc R, Sedarati F, Neate C, Reginster JY 2008 Monthly oral ibandronate is effective and well tolerated after 3 years: The MOBILE long-term extension. Clin Rheumatol 27: 955–960.
  • 149
    Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W 2007 A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 40: 1238–1243.
  • 150
    Bonnick S, Saag KG, Kiel DP, McClung M, Hochberg M, Burnett SA, Sebba A, Kagan R, Chen E, Thompson DE, de Papp AE 2006 Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 91: 2631–2637.
  • 151
    Papapoulos SE, Schimmer RC 2007 Changes in bone remodeling and antifracture efficacy of intermittent bisphosphonate therapy: Implications from clinical studies with ibandronate. Ann Rheum Dis 66: 853–858.
  • 152
    Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189–1199.
  • 153
    Grbic J, Black D, Lyles K, Reid D, Bucci-Rechtweg C, Mesenbrink P, Orwoll E, Eriksen EF 2008 Osteonecrosis of the jaw: Zoledronic acid 5 mg experience in a variety of osteoporosis indications. J Bone Miner Res 23: S69.
  • 154
    Ravn P, Christensen JO, Baumann M, Clemmesen B 1998 Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: Prediction of bone mass changes during treatment. Bone 22: 559–564.
  • 155
    Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM 2004 Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: Results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 19: 1259–1269.
    Direct Link:
  • 156
    Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, Zhou X, Grauer A 2008 Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 19: 365–372.
  • 157
    Schwartz AV, Bauer DC, Garnero P, Santora AC, Palermo L, Black DM 2005 Change in bone turnover markers following discontinuation of long-term alendronate in FLEX. J Bone Miner Res 20: S281.
  • 158
    Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG 2008 Risk of hip fracture after bisphosphonate discontinuation: Implications for a drug holiday. Osteoporos Int 19: 1613–1620.
  • 159
    Giannobile WV, Lynch SE, Denmark RG, Paquette DW, Fiorellini JP, Williams RC 1995 Crevicular fluid osteocalcin and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP) as markers of rapid bone turnover in periodontitis. A pilot study in beagle dogs. J Clin Periodontol 22: 903–910.
    Direct Link:
  • 160
    Oringer RJ, Palys MD, Iranmanesh A, Fiorellini JP, Haffajee AD, Socransky SS, Giannobile WV 1998 C-telopeptide pyridinoline cross-links (ICTP) and periodontal pathogens associated with endosseous oral implants. Clin Oral Implants Res 9: 365–373.
    Direct Link:
  • 161
    Palys MD, Haffajee AD, Socransky SS, Giannobile WV 1998 Relationship between C-telopeptide pyridinoline cross-links (ICTP) and putative periodontal pathogens in periodontitis. J Clin Periodontol 25: 865–871.
    Direct Link:
  • 162
    Giannobile WV 1999 C-telopeptide pyridinoline cross-links. Sensitive indicators of periodontal tissue destruction. Ann N Y Acad Sci 878: 404–412.
    Direct Link:
  • 163
    Al-Shammari KF, Giannobile WV, Aldredge WA, Iacono VJ, Eber RM, Wang HL, Oringer RJ 2001 Effect of non-surgical periodontal therapy on C-telopeptide pyridinoline cross-links (ICTP) and interleukin-1 levels. J Periodontol 72: 1045–1051.
  • 164
    Garnero P, Gineyts E, Schaffer AV, Seaman J, Delmas PD 1998 Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease. Arthritis Rheum 41: 354–360.
    Direct Link:
  • 165
    Delmas PD 1999 Biochemical markers of bone turnover in Paget's disease of bone. J Bone Miner Res 14: S2 ; 66–69.
  • 166
    Alvarez L, Guanabens N, Peris P, Vidal S, Ros I, Monegal A, Bedini JL, Deulofeu R, Pons F, Munoz-Gomez J, Ballesta AM 2001 Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease. Bone 29: 447–452.
  • 167
    Peris P, Alvarez L, Monegal A, Guanabens N, Duran M, Echevarria M, Ros I, Ballesta AM, Munoz-Gomez J 2002 Effect of surgical menopause and Paget's disease of bone on the isomerization of type I collagen carboxyterminal telopeptide: Evolution after antiresorptive therapy. J Bone Miner Metab 20: 116–120.
  • 168
    Alexandersen P, Peris P, Guanabens N, Byrjalsen I, Alvarez L, Solberg H, Cloos PA 2005 Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone. J Bone Miner Res 20: 588–595.
    Direct Link:
  • 169
    Shankar S, Hosking DJ 2006 Biochemical assessment of Paget's disease of bone. J Bone Miner Res 21: S2 ; 22–27.
    Direct Link:
  • 170
    Collins MT, Kushner H, Reynolds JC, Chebli C, Kelly MH, Gupta A, Brillante B, Leet AI, Riminucci M, Robey PG, Bianco P, Wientroub S, Chen CC 2005 An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone. J Bone Miner Res 20: 219–226.
    Direct Link:
  • 171
    Chapurlat RD, Hugueny P, Delmas PD, Meunier PJ 2004 Treatment of fibrous dysplasia of bone with intravenous pamidronate: Long-term effectiveness and evaluation of predictors of response to treatment. Bone 35: 235–242.
View Full Article (HTML) Get PDF (542K)